Analysis Sets and Inference in Clinical Trials

Therapeutic Innovation and Regulatory Science

Volumn 47, Issue 4, 2013, Pages 455-459

  Rosenkranz, Gerd K ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

analysis sets; compliance; effectiveness; efficacy

Indexed keywords

RETINOL;

ARTICLE; BIOSTATISTICS; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMPLIANCE (PHYSICAL); CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL (TOPIC); EXPERIMENTAL THERAPY; HUMAN; INTENTION TO TREAT ANALYSIS; MORTALITY; OUTCOME VARIABLE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; VITAMIN SUPPLEMENTATION;

EID: 84879509617     PISSN: 21684790     EISSN: 21649200     Source Type: Journal    
DOI: 10.1177/2168479013486270     Document Type: Article

References (13)

1. Wiens BL,Zhao W.The role of intention-to-treat analysis in non-inferiority trials.Clin Trials. 2007;4:286-291.
2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Statistical Principles for Clinical Trials E9. 1998. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf.
3. Sommer A,Zeger SL.On estimating efficacy from clinical trials.Stat Med. 1991;10:45-52.
4. Sheiner LB,Rubin DB.Intention-to-treat analysis and the goals of clinical trials.Clin Pharmacol Ther. 1995;57:6-15.
5. Frangakis CE,Rubin DB.Principal stratification in causal inference.Biometrics. 2002;58:21-29.
6. Jin H,Rubin DB.Principal stratification for causal inference with extended partial compliance.J Am Stat Assoc. 2008;103:101-111.
7. Robins JM.Correcting for non-compliance in randomized trials using structural nested mean models.Commun Stat Theory Methods. 1994;23:2379-2412.
8. Fischer-Lapp K,Goetghebeur E.Practical properties of some structural mean analyses of the effect of compliance in randomized trials.Control Clin Trials. 1999;20:531-546.
9. Kenward MG,Rosenkranz GK.Joint modeling of outcome, observation time and missingness.J Biopharm Stat. 2011;21:252-262.
10. Rosenkranz GK.The impact of randomization on the analysis of clinical trials.Stat Med. 2011;30:3075-3487.
11. Ware JH,Hamel MB.Pragmatic trials-guides to better patient care?.N Engl J Med. 2011;364:1685-1687.
12. O'Neill RT,Temple R.The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.Clin Pharmacol Ther. 2012;91:550-554.
13. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: National Academies Press; 2010:.